Skip to content

Author

C. Lovly

We have 2 of 279 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world clinical outcomes among patients with EGFR-mutated (Ex19del/L858R) metastatic NSCLC treated at City of Hope with osimertinib monotherapy by TP53 alteration status.

703 Background: Epidermal growth factor receptor mutations (EGFRm) occur in ~15% of non-small cell lung cancer (NSCLC) cases, with exon 19 deletions (Ex19del) and exon 21 L858R substitutions (L858R) comprising 85-90%. Osimertinib (Osi) monotherapy (mono) is one of the first-line (1L) treatment options, while mo...

S. Gruber, P. Vadagam, L. Morrison et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.